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Abstract: Fenugreek is a common herb possessing several bioactive components including
diosgenin. Here, dietary fenugreek seed flour and diosgenin were evaluated on a model of
endothelium-dependent vasorelaxation by abdominal aortas isolated from rats receiving high-fat,
high-sugar diet (HFHSD). 60 male Wistar rats were randomized into six groups: (i) negative control
getting conventional rat feed regimen; (ii) positive control receiving HFHSD; (iii) a test group fed
2 g/kg bw/day fenugreek seed flour (containing 10 mg/kg bw/day diosgenin) + HFHSD; (iv) three
test groups fed 1, 10 and 50 mg/kg bw/day diosgenin + HFHSD. Alimentary treatments were
carried out for six weeks. The abdominal aortas were isolated, and 2 mm wide rings were sectioned
off and mounted at a resting tension of 10 mN in organ baths containing Krebs solution (36 ◦C)
exposed to 95% O2 and 5% CO2. After 60-min incubation, a norepinephrine concentration-response
(E/c) curve was generated to determine their half-maximal effective concentration (EC50) value.
After 60-min wash-out, a pre-contraction with norepinephrine EC50 was made, followed by an
acetylcholine E/c curve. Plasma glutathione levels, glutathione-handling enzyme activities and blood
antioxidant capacities were also determined. HFHSD significantly decreased the dilatory response to
acetylcholine and increased plasma glutathione levels and these effects were significantly reversed by
fenugreek seed flour, 10 and 50 mg/kg bw/day diosgenin. Both fenugreek and diosgenin treatments
prevent HFHSD-induced endothelial dysfunction and redox changes. As fenugreek treatment
was more effective at lower acetylcholine concentrations than diosgenin treatments, components of
fenugreek other than diosgenin may contribute to the beneficial effects of dietary fenugreek seed flour.
Keywords: endothelial dysfunction; metabolic syndrome; obesity; type 2 diabetes mellitus; fenugreek;
Trigonella foenum-graecum; diosgenin; endothelium-dependent vasorelaxation; Wistar rat
1. Introduction
Metabolic syndrome (MetS) is a group of metabolic disorders characterized by the presence
of at least three of five pathological conditions, described as follows: central obesity, hypertension,
hyperglycemia, hypertriglyceridemia and decreased level of high-density lipoprotein (HDL) [1,2].
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MetS is one of the most prevalent and rapidly increasing challenges to public health worldwide, with
onset and pathogenesis associated with frequent sedentary lifestyle choices and high calorie intake in
affluent societies. MetS patients have a five-fold higher risk of developing type 2 diabetes mellitus
(T2DM) and two-fold risk for cardiovascular diseases (CVD) than the general human population [3,4].
A major commonality of these pathologies is that they all engender impairment of endothelial function.
Endothelial dysfunction (ED) forms the basis of atherosclerosis, which is the most important risk factor
for CVD [5,6].
Although the vascular endothelium consists only of a thin monolayer of cells covering the
inner surface of blood vessel wall, this tissue plays a crucial role in maintenance of a normal
circulation. Beyond its barrier function, endothelium acts as a paracrine organ producing a
number of transmitter molecules that contribute to the regulation of a wide range of processes
including hemostasis, inflammation, vascular proliferation and vascular tone [7,8]. Endothelial
cells synthesize both vasodilators (such as endothelium-derived relaxing factor (nitric oxide: NO),
endothelium-derived hyperpolarizing factor, prostacyclin (PGI2)) and vasoconstrictor compounds
(e.g., endothelins and leukotrienes) [9,10]. Certain metabolic, hormonal and homeostatic conditions,
including hyperglycemia, hyperinsulinemia, hypertension, obesity, decreased level of high-density
lipoprotein cholesterol (HDL), increased levels of insulin-like growth factor 1, fatty acids, triglycerides,
low-density lipoprotein cholesterol (LDL), angiotensin II and plasminogen activator inhibitor-1, impair
the barrier and regulatory functions of endothelial cells and thereby lead to ED. A major consequence of
ED is that the balance between vasoconstriction and vasorelaxation is disrupted resulting in detrimental
vasoconstriction that progresses into hypertension [11]. A further consequence of ED is a concomitant
disharmony between coagulation and fibrinolysis, which can lead to enhanced thrombus formation.
These deleterious processes, when added to other effects of hypertension, create conditions that favor
atherosclerosis and elevated risk for cardiovascular events, especially stroke and acute myocardial
infarction [12]. The most important underlying molecular mechanisms leading to ED are decreased
production and/or increased degradation of NO, diminished responsiveness to NO, depletion of
NADPH, increased NADH/NAD+ ratio, elevated levels of protein kinase C and advanced glycation
end products; in general: increased oxidative stress and decreased antioxidant capacities [13].
The complexity of overlapping signaling pathways leading to ED has made identification of the
primary triggering events problematic. A schematic representation of signaling pathways contributing
to ED, made by Hsueh et al., provided enhanced clarity by delineating these processes in relation
to progression of insulin resistance. This graphic construct suggests that hyperinsulinemia may act
as a “zero point” event, which alters endothelial function in ways that progress into MetS. MetS,
especially with obesity, increases systemic inflammation, oxidation of NO and LDL cholesterol, thereby
increasing the risk of thrombosis, a condition that also adversely affects endothelial function. MetS is
associated with impaired glucose tolerance and T2DM onset, two conditions that increase the risk of
atherosclerosis [14].
In the present report, fenugreek seed flour was investigated as a possible countermeasure to the
above-mentioned pathological changes, with special regard to the restoration of endothelial function.
The rationale for selecting this plant is based on its “generally recognized as safe” (GRAS) status
as a component of human diet, along with its known antidiabetic properties and wide availability.
Fenugreek (Trigonella foenum-graecum) is one of the most commonly used medicinal herbs in the
prevention and treatment of T2DM in many East Asian cultures. A component of this plant, diosgenin,
along with 4-isohydroxyleucin and galactomannan, are the components thought to be the most
responsible for the beneficial effects of fenugreek on MetS and T2DM [15]. Diosgenin is a phytosteroid
sapogenin that can be chemically converted into several medically used steroid products, notably
progesterone, pregnenolone and cortisone. Although metabolic effects of fenugreek have been
widely studied, little definitive data has been published regarding its effects on the vasculature.
It has, nevertheless, been noted that aqueous extracts of fenugreek leaf [16] and alcoholic extracts
of fenugreek seed [17] were found to have beneficial effects in a streptozotocin-induced diabetic rat
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model. In contrast to fenugreek, several investigations dealt with diosgenin, primarily focusing on its
ability to improve the condition of vasculature and/or endothelium in diabetic rats [18–24]. However,
the underlying cellular and molecular mechanisms concerning diosgenin’s effects have remained to be
defined at the time of this writing.
For the present investigation, a rat model of early-stage MetS was used. Wistar rat is a widely
used experimental model of the disturbed carbohydrate and/or lipid metabolism [25,26].
2. Results
2.1. Characteristics of the Animal Model
During the 6-week dietary treatment, rats showed a moderate (and statistically non-significant)
body weight gain in every experimental group. The average weight gain was the biggest in the
fenugreek group (treated with fenugreek seed flour: 85 g) followed by the positive control group
(received HFHSD only: 69.9 g), 50 mg diosgenin group (got 50 mg/kg bw/day diosgenin: 55.9 g),
10 mg diosgenin group (received 10 mg/kg bw/day diosgenin: 40.6 g) and 1 mg diosgenin group
(got 1 mg/kg bw/day diosgenin: 35.4 g), while the body weight gain was the smallest in the negative
control group (kept conventionally: 30.9 g) (Figure 1a).
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Figure 1. The effect of high-fat, high-sugar diet (HFHSD) (positive control: Co+), 2 g/kg bw/day 
fenugreek seed flour in addition to HFHSD (FSF), 1, 10 and 50 mg/kg bw/day diosgenin in addition 
to HFHSD (1D, 10D and 50D, respectively) on the body weight (a), fasting plasma glucose level (b) 
and fasting plasma insulin level (c) of Wistar rats. The negative control group (Co−) consisted of rats 
receiving conventional rat food and tap water. In the panel (a), the left one of columns with the same 
color and pattern indicates the initial body weight, while the right one shows the body weight after 
the 6-week dietary treatment. The columns represent the average values of the given groups (+SEM). 
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Figure 1. The effect of high-fat, high-sugar diet (HFHSD) (positive control: Co+), 2 g/kg bw/day
fenugreek seed flour in addition to HFHSD (FSF), 1, 10 and 50 mg/kg bw/day diosgenin in addition
to HFHSD (1D, 10D and 50D, respectively) on the body weight (a), fasting plasma glucose level (b)
and fasting plasma insulin level (c) of Wistar rats. The negative control group (Co−) consisted of rats
receiving conventional rat food and tap water. In the panel (a), the left one of columns with the same
color and pattern indicates the initial body weight, while the right one shows the body weight after the
6-week dietary treatment. The columns represent the average values of the given groups (+SEM).
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Neither fasting plasma glucose concentrations nor fasting plasma insulin levels, measured after
the six-week dietary treatment, differed significantly among the groups (Figure 1b,c).
These results indicate that, in this model, no obesity or insulin resistance, two important
pathological conditions characteristic of MetS, developed. Consistently, no significant effect of
alimentary fenugreek or diosgenin treatment on the body weight and glucose homeostasis could
be observed.
2.2. Response to Norepinephrine
The maximal contractile forces that evolved in the presence of the different NE concentrations
did not differ significantly among the six groups (Figure 2). The statistically non-significant increase
in the NE-susceptibility of the positive control group (subjected to HFHSD only) might indicate a
moderate decrease in the basal production and/or availability of NO in comparison with that/those of
the negative control group (encompassing rats kept conventionally). If that were the case, the applied
alimentary fenugreek and diosgenin treatments might slightly improve vascular NO homeostasis
(Figure 2).
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Figure 2. The effect of norepinephrine (NE) on the abdominal aorta isolated from rats treated with
dietary fenugreek seed flour or different doses of diosgenin in addition to high-fat, high-sugar
diet (HFHSD), and from rats forming the positive (receiving HFHSD only) and negative (getting
conventional rat food and tap water) controls. The axis x shows the co on logarith of olar
concentration of E, hile the axis y indicates the contractile force of the aortic rings (over the resting
level). The length of the rings as the sa e throughout the study. The sy bols represent the effect of
E averaged ithin the groups ( SE ).
2.3. Response to Acetylcholine
In the negative control group (consisting of rats kept conventionally), 10–100 µmol/L acetylcholine
(Ach) could totally abolish the pre-contraction of aortic rings elicited by NE (used in EC50
concentration). In contrast, responses to Ach in the positive control group (receiving HFHSD only)
showed a significant decrease (at 10, 100 and 1000 µmol/L Ach concentrations) when compared
with those in the negative control group (Figure 3a). Thus, despite the absence of obesity and insulin
resistance reflected by the results presented above (Figure 1), our HFHSD rat model displayed impaired
endothelial function characteristic of disturbed carbohydrate and/or lipid metabolism.
The 2 g/kg bw/day fenugreek seed flour treatment significantly improved the response to Ach
(even at relatively low Ach concentrations), almost totally preventing the deteriorative effect of HFHSD
(Figure 3b). Treatment with diosgenin, a fenugreek component thought to be important regarding
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the beneficial effects of fenugreek preparations, can fairly mimic the action of fenugreek seed flour
treatment in the present model. Although 1 mg/kg bw/day diosgenin failed to reach a statistically
significant beneficial effect (due to the high scatter in the results reflecting very different individual
responses to Ach in the 1 mg diosgenin group) (Figure 3c), 10 and 50 mg/kg bw/day diosgenin
significantly augmented the Ach-induced relaxation (especially at medium and high Ach levels) in
comparison with the positive control group (Figure 3d,e). Nevertheless, responses to Ach in the
fenugreek and diosgenin groups did not differ from one another in a statistically significant manner.
It should be noted that the effect of 2 g/kg bw/day fenugreek seed flour treatment (equivalent to
10 mg/kg bw/day diosgenin treatment regarding its diosgenin content) showed two interesting
differences in comparison with the action of diosgenin treatments. First, the shape of Ach
concentration-response (E/c) curve was the least regular in the fenugreek group, probably owing to the
complex effects afforded by the numerous components of fenugreek seed flour. Second, only fenugreek
treatment could significantly enhance the relaxation at 10 nmol/L Ach concentration (a relatively low
value), although the maximal relaxation evoked by Ach in the fenugreek group was (non-significantly)
smaller than that in the negative control and diosgenin groups. It is also interesting that average effects
of the different diosgenin treatments on the response to Ach were quite similar to one another, the
increase of diosgenin dose predominantly reduced the scatter of the results, i.e., it homogenized the
response to Ach. For further evaluation of the Ach E/c curves, see Appendix A.
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Figure 3. The effect of acetylcholine (Ach) on the abdominal aorta isolated from rats treated with dietary
fenugreek seed flour (panel (b)) or different doses of diosgenin in addition to high-fat, high-sugar
diet (HFHSD) (panel (c–e)), and from rats forming the positive (receiving HFHSD only) and negative
(receiving conventional rat food and tap water) controls (panel (a)). All aortic rings underwent a
pre-contraction evoked by norepinephrine (NE) before the administration of Ach. The axis x shows the
common logarithm of molar concentration of Ach, while the axis y indicates the effect as a percentage
decrease of the initial contractile force of aortic rings. The symbols represent the effect of Ach averaged
within the groups (±SEM). Asterisks denote the significance level of differences between groups
indicated with black colored symbols and lines (*: p < 0.05; **: p < 0.01).
2.4. Results of Assays for Blood Redox Status
Results of the pr sent invest gatio concerning the hanges in plasma glutathione levels,
glutathio e-handling enzyme activitie and antioxidant capacity in response o the d ffe nt d etary
treatments allow us to make s me assumptio s. The HFHSD t nded to shift the oxidor ductive
balance to the oxidative direction in the blood, indicated by an increase in oxidized glutathione level
of positive control group (receiving only HFHSD) as compared to the negative control group (getting
normal diet) (Figure 4a). Probably as a result of compensatory processes, the oxidative stress caused by
HFHSD also increased the level of the reduced form of glutathione in the plasma of positive controls
(Figure 4b) that led to a practically unchanged reduced to oxidized glutathione ratio (Figure 4c). It is
clearly seen, furthermore, that the treatment with either diosgenin or fenugreek dramatically decreased
the concentration of glutathione, equally affecting both of its forms (Figure 4). This phenomenon
could also be considered as a result of counteracting processes against oxidative stress caused by
HFHSD, if assuming that diosgenin and some compounds of fenugreek (including diosgenin itself)
acted as effective antioxidants rendering sufficient oxidoreductive balance even at low glutathione
plasma levels.
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Figure 4. The effect of high-fat, high-sugar diet (HFHSD) (positive control: Co+), 2 g/kg bw/day
fenugreek seed flour in addition to HFHSD (FSF), 1, 10 and 50 mg/kg bw/day diosgenin in addition to
HFHSD (1D, 10D and 50D, respectively) on plasma levels of the oxidized (a) and reduced (b) forms of
glutathione, furthermore on the ratio of reduced to oxidized glutathione (c) in Wistar rats. The negative
control group (Co−) consisted of rats receiving conventional rat food and tap water. The columns
represent the average values of the given groups (+SEM). Asterisks indicate the significance level of
differences between groups (*: p < 0.05; **: p < 0.01; ***: p < 0.001; ****: p < 0.0001).
Although activities of glutathione peroxidase, an enzyme which reduces the peroxide (O–O)
moiety to an O–H moiety via oxidizing the reduced form of glutathione, did not show considerable
differences among the groups (Figure 5a), activities of glutathione reductase, which regenerates
the oxidized glutathione to a reduced one, proved to be significantly lower in the diosgenin- and
fenugreek-treated groups as compared to both the negative and positive controls (Figure 5b). This latter
finding corroborates the assumption described above, i.e., diosgenin and perhaps some other fenugreek
compounds are effective antioxidants that decrease the need for glutathione. The counterbalancing
function of glutathione (and possibly other endogenous oxidoreductive) system(s), which seem(s) to
maintain a dynamic functional equilibrium with exogenous factors (e.g., dietary diosgenin), may be
reflected in the finding that the antioxidant capacities of lipid- (Figure 6a) as well as water-soluble
(Figure 6b) substances of the blood did not differ in a considerable way among the experimental
groups receiving different dietary treatments.
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fenugreek seed flour in addition to HFHSD (FSF), 1, 10 and 50 mg/kg bw/day diosgenin in addition 
to HFHSD (1D, 10D and 50D, respectively) on the antioxidant capacity of lipid- (ACL; (a)) and water-
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Figure 5. The effect of high-fat, high-sugar diet (HFHSD) (positive control: Co+), 2 g/kg bw/day
fenugreek seed flour in addition to HFHSD (FSF), 1, 10 and 50 mg/kg bw/day diosgenin in addition
to HFHSD (1D, 10D and 50D, respectively) on plasma activities of two major glutathione-handling
enzymes, glutathione peroxidase (a) and glutathione reductase (b), in Wistar rats. The negative control
group (Co−) consisted of rats receiving conventional diet. The columns represent the average values
of the given groups (+SEM). Asterisks indicate the significance level of differences between groups
(*: p <0.05; **: p < 0.01; ****: p < 0.0001).
In summary, diosgenin (and maybe some other components of fenugreek seed) appear(s) to
substitute the endogenous antioxidant factors (including glutathione) to maintain the vascular redox
balance. So, changes in endogenous antioxidant mechanisms (Figures 4–6) can be considered to
be rather compensatory responses to the presence of exogenous antioxidants than causes of the
improvement of Ach responsiveness seen after addition of diosgenin or fenugreek (Figure 3). It means
that diosgenin (and possibly some other fenugreek components) was/were more potent in preserving
the endothelium-dependent vasorelaxation during HFHSD than the endogenous antioxidant factors.
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3. Discussion
A primary outcome of the present study is that 2 g/kg bw/day dietary fenugreek seed flour,
and 10 and 50 mg/kg bw/day dietary diosgenin (all applied in addition to HFHSD) practically
completely prevented ED produced by HFHSD alone. Furthermore, fenugreek seed flour appears to
augment endothelium-dependent vasorelaxation at lower Ach levels than diosgenin, suggesting that
components of fenugreek other than diosgenin might contribute to the beneficial effect of fenugreek
seed flour. It has been also found that HFHSD alone markedly increased the plasma levels of both
oxidized and reduced glutathione, while this treatment did not significantly affect the activity of either
glutathione peroxidase or glutathione reductase. In contrast, both fenugreek and diosgenin caused a
dramatic decrease in plasma levels of both oxidized and reduced glutathione, with a simultaneous
remarkable attenuation of glutathione reductase (but not glutathione peroxidase) activity. Interestingly,
the blood antioxidant capacity has been found relatively insensitive to the different feed regimens used
in the present study, thus, underscoring the efficiency and flexibility (and relative resistance to dietary
factors) of processes that maintain redox balance in the blood. These results suggest that antioxidant
agents within fenugreek seed (especially diosgenin) can modify the regulatory pathways underlying
the redox balance of the blood (in a complex manner) that may contribute to the beneficial effect of
these compounds on endothelium-dependent arterial dilatory response under disrupted metabolic
conditions. In addition, our results have confirmed the previous observation that ED is an early sign of
disturbed carbohydrate and lipid metabolism. Moreover, our findings indicate that a decrease in the
endothelium-dependent arterial relaxation caused by HFHSD can precede the manifest hyperglycemia
and hyperinsulinemia.
NO, a main vasodilatory substance, is generated through conversion of L-arginine to L-citrulline
by three types of NO-synthases (NOSs): neuronal (nNOS or NOS1), inducible (iNOS or NOS2) and
endothelial (eNOS or NOS3) ones. Endothelium expresses eNOS, while vascular smooth muscle was
reported to contain all three NOS isoforms [27]. In the vascular smooth muscle cells, NO activates
the guanylate cyclase causing an increase in cGMP level and consequent activation of protein kinase
G that induces vasorelaxation [28]. Beyond this classic effect, activating the protein kinase B (Act)
pathway, NO exerts protective and regenerative effects on the endothelial cells, inhibits proliferation
and migration of the smooth muscle cells [29–31]; thus, it acts as an anti-atherosclerotic agent—if it can
reach its physiological targets in the arterial wall to induce its physiological effects. Namely, when
the redox balance in the vascular wall shifts towards the oxidative direction, reactive oxygen species
(ROS), e.g., superoxide anion (O2−), transform NO into reactive nitrogen species (RNS) (in the case
of O2−, into peroxynitrite) that results in nitrosative stress besides the oxidative one [32]. Although
ROS are continuously generated even during the normal metabolism, ROS production, in response
to all types of stress, shows a dramatic increase leading to the condition known as oxidative stress.
Oxidative stress results in tissue damage and consequent inflammation, affecting a variety of metabolic
pathways including NO homeostasis [33]. On one hand, expression of iNOS markedly increases
followed by a substantial rise of NO (and O2−, see below) production. On the other hand, NOS
isoforms (including eNOS) undergo a conformational change called uncoupling, as a result of which
they will produce O2− instead of NO [34]. Paradoxically, in spite of the increased NO production
in oxidative stress, deficiency of NO is seen at the level of the physiological NO-induced pathways,
because of the enhanced NO consumption during RNS formation. The above-mentioned processes
highlight the crucial role of redox status in the evolution of CVD [35].
Reduced glutathione (GSH) is the most significant small antioxidant molecule in living organisms,
accomplishing the elimination of ROS and RNS, reduction of lipid peroxides, and protection of SH–
group containing enzymes from inactivation (via S-glutathionylation). During its reducing action,
GSH turns into GSSG (oxidized glutathione (glutathione disulfide)), the oxidized form made through
SH-bridge. GSH is transformed back in a NADPH-dependent reaction catalyzed by glutathione
reductase, ensuring the redox balance in healthy organisms [36]. Deficiency of glutathione-related
antioxidant defenses exists e.g., in atherosclerotic plaques [37].
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Earlier studies have demonstrated that diosgenin influences the carbohydrate homeostasis at
several molecular targets, being capable of effectively reducing hyperglycemia in pharmacologically
induced rat diabetes models [38,39]. The underlying mechanisms are multifactorial and include
restoration of pancreatic β-cell function, modulation of hepatic enzymes (regulating gluconeogenesis
and antioxidant capacity of the liver) [40], promotion of adipocyte differentiation, inhibition
of macrophage infiltration into adipose tissue, and decrease of expression of inflammatory
genes [41]. It has been also observed that diosgenin decreases expression of the C/EBP homologous
protein (CHOP) leading to reduced stress of endoplasmic reticulum in pancreatic islet β-cells.
Moreover, diosgenin enhances expression of peroxisome proliferator-activated receptor gamma
(PPRγ) that results in increased adipocyte differentiation, decreased adipocyte size and ectopic
fat accumulation [38]. In addition, diosgenin, acting as a PPRγ agonist, may mimic the effect of
thiazolidinediones, classic insulin-sensitizing drugs, in the peripheral tissues [42].
Disturbance to lipid synthesis and accumulation is a characteristic phenomenon in obesity and
MetS that promotes development of atherosclerosis and CVD. Thus, maintenance or restoration of
normal lipid homeostasis is a major goal in the therapy of MetS [43,44]. Lipid metabolism is controlled
by sterol-regulatory, element-binding proteins (SREBPs), a family of membrane-bound transcription
factors. SREBPs activate expression of several genes associated with lipid absorption, excretion and
metabolism [45]. SREBP-1c is influenced by liver X receptor-a (LXRa), which functions primarily as a
sterol sensor, with additional roles in bile acid synthesis and metabolism, cholesterol movement, fatty
acid synthesis and lipoprotein metabolism [46]. It has been recently demonstrated that diosgenin can
ameliorate dyslipidemia through inhibiting transactivation of LXRa in KK-Az mice [47]. This finding
corroborates the observation that diosgenin increases levels of antioxidant and hepatoprotective
enzymes in the blood plasma and liver, with concomitant improvement of β-cell regeneration and
insulin secretion in streptozotocin-induced diabetic rats [40]. It has been also found that diosgenin
increases the phosphorylation of AMP-activated protein kinase (AMPK) and acetyl-CoA carboxylase
(ACC) in HepG2 cells, furthermore it suppresses LXRa in a rat model of non-alcoholic fatty liver
disease (NAFLD), thus preventing development of NAFLD [48].
Ex vivo studies have revealed that diosgenin can directly modulate the function of arterial smooth
muscle by regulating cell viability and blocking smooth muscle cell migration [49], furthermore it
can evoke endothelium-dependent vasorelaxation that could be blocked by an eNOS inhibitor [50].
Moreover, in cultured human endothelial cells, diosgenin has been found to ameliorate FFA-induced
endothelial dysfunction and insulin resistance via inhibiting the IKKβ and IRS-1 pathways [51].
Diosgenin is not the only phytochemical responsible for the beneficial effects of fenugreek.
Fenugreek seed contains large amounts of amino acids, including 4-hydroxyisoleucine (4-OH-Ile)
that stimulates insulin secretion and improves insulin sensitivity [52–55]. The underlying mechanism
encompass enhancement of glucose uptake by translocation of GLUT4 (glucose transporter 4) to the
plasma membrane [56]. Moreover, 4-OH-Ile also exerts anti-inflammatory action via reducing TNF-α
mRNA expression [57,58]. Galactomannan, another component of fenugreek, inhibits some lipid- and
carbohydrate-hydrolyzing enzymes, such as α-glucosidase, that leads to decreased lipid and glucose
absorption [59–61]. These properties of fenugreek compounds have been commercialized in products
for general use, such as FenfuroTM, a patented dietary supplement containing fenugreek seed extract
that has proven to be useful in the therapy of T2DM [62].
In association with the metabolic effects mentioned above, fenugreek seed and diosgenin
both exhibit anti-inflammatory properties, the precise mechanism of which is not fully defined
yet. Nevertheless, it has been observed that diosgenin inhibits expression of VCAM-1 (vascular
cell adhesion molecule) and ICAM-1 (intracellular adhesion molecule), proteins involved in the
pathogenesis of atherosclerosis, abolishes TNF-α induced production of intracellular ROS and inhibits
NF-κB and IκB kinase activation, along with subsequent degradation of IκBα, and nuclear translocation
of NF-κB. These findings show that diosgenin is a potent agent for inhibiting the formation and growth
of atherosclerotic lesions [24]. Decrease of ROS formation by diosgenin is especially important, because
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almost all ROS-related pathologic processes involve transformation of NO into peroxynitrite that
conversion diminishes the bioavailability of NO and leads to the condition called ED [32].
Our finding, i.e., ED can be an early sign of metabolic diseases, is in agreement with results of
several previous studies. In an investigation using rabbits fed with high-fat diet (HFD) for 2–8 weeks,
ED developed already at the second week [63]. High level of free fatty acids (FFAs) thought to play a
prominent role to evoke ED, because FFAs downregulate the AMPK/PI3K/Akt/eNOS signaling
pathway [64], activate the NADPH oxidase leading to enhanced ROS generation and oxidative
stress [65], and also activate the protein kinase C and NF-κB pathways hampering the vascular
insulin signaling [66]. ED has been found to possess a prognostic impact on recognizing CVD [67],
moreover it can be considered as an independent risk factor of CVD [68,69]. Consistently, in our
early stage MetS model (with six-week HFHSD), ED developed even at normal plasma glucose and
insulin levels.
According to the classic concept of the regulation of arterial tension, one of the most important
roles of the endothelium is to respond to chemical stimuli such as Ach, by release of vasodilatory agents,
notably NO, which acts on adjacent smooth muscle cells to relax and increase diameter of the blood
vessel [70,71]. However, a new vasodilatory concept has recently been proposed which is that arterial
smooth muscle is more than just a passive recipient of endothelial NO, and in fact it is a paracrine
effector that responds to Ach by release of NO, thereby contributing to vascular tone regulation [72].
In this scenario, the role of the endothelial layer is predominantly to protect the arterial media
from oxidative stressors (such as superoxide anion) and thereby to maintain the appropriate redox
balance in the tissue compartment of arterial smooth muscle [27,73]. This concept is supported by the
observation that presence of effective superoxide scavengers (tempol and N-acetyl-L-cysteine) allowed
the endothelium-deprived rat aorta sections to partially preserve their dilatory response capacity to
Ach. This observation suggests that the major underlying mechanism, by which endothelial cells
enable the so-called endothelium-dependent vasorelaxation, is to protect the smooth muscle-derived
NO from oxidative stressors and to allow it to mediate a dilatory action [72].
The precise mechanism of achieving a balance between vasoconstrictive and vasodilatory processes
remains to be fully characterized. It nevertheless may be concluded that a complex relationship exists
between endothelial function and redox conditions in the vasculature: the physiological endothelial
function ensures the appropriate oxidoreductive state in the microenvironment of vascular smooth
muscle (maintaining the intact smooth muscle responsiveness), while oxidative stress in the circulation
damages the function of endothelial cells (shifting the redox balance in the media and thereby leading to
weaker smooth muscle response to vasodilators). In this respect, results reported by the present study
have provided further evidence in support of the significance of redox balance to sustain the normal
dilatory susceptibility of arteries and thereby the physiological arterial tension. In addition, results
of the present study demonstrate the significant antioxidant property of fenugreek seed compounds,
especially that of diosgenin. Results of our functional assays indicate that dietary fenugreek seed
flour as well as diosgenin (used in sufficiently high doses) can significantly improve, and indeed,
practically restore the HFHSD-damaged arterial response to Ach, a classic vasodilatory signal molecule
(Figure 3). Taking into consideration the functional findings reported here (Figure 3, Figure A1,
Table A1) together with results of assays for blood redox status (Figures 4–6), it is proposed that
improvement of endothelium-dependent vasorelaxation in response to fenugreek and diosgenin
treatment was mediated by the antioxidant action of diosgenin and possibly by other fenugreek
components. The above findings and interpretations, nevertheless, raise an important question: why
is it that decreased antioxidant capacity was not detected in the plasma of animals receiving only
HFHSD (positive controls), along with elevated plasma antioxidant capacity in the fenugreek- and
diosgenin-treated animals, in comparison with the negative controls (Figure 6)? A speculative account
for these observations is that the redox balance perturbed by HFHSD may be more easily compensated
in the bloodstream than in the arterial media. An alternative (but not exclusive) explanation may be
that in response to HFHSD, a special kind of redox balance developed in the blood. This redox state,
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although it seemed to be normal according to outcomes of the assays reported here, was insufficient to
maintain physiological endothelial function and/or the intact smooth muscle responsiveness. In turn,
scavengers of reactive oxygen species (such as diosgenin) could substantially increase the antioxidant
capacity in the arterial wall without significantly affecting the redox balance in the blood, which may
be due to their lipophilic property.
In summary, both fenugreek and diosgenin can prevent the impairment of arterial endothelial
function (characterized by the response to Ach) developed during HFHSD. This beneficial effect
may be associated with the simultaneous decrease in plasma glutathione levels and glutathione
reductase activity that may reflect the reduced need for endogenous antioxidants in the presence
of exogenous ones. Although patterns of beneficial effects of fenugreek and diosgenin are quite
similar, they show some moderate differences. Namely, at lower Ach levels, fenugreek can produce
somewhat stronger enhancement in the response to Ach than diosgenin. In light of the present
results, fenugreek seed preparations may play an important role in future supplement therapy of
metabolic disorders (including MetS), even at their early stage with seemingly intact body weight and
carbohydrate homeostasis.
4. Materials and Methods
4.1. Materials
The following chemicals and preparations were used: conventional rat food (S8106-S011 SM
R/M-Z + H, obtained from Ssniff Spezialdiäten GmbH, Soest, Germany), high-fat rat food (rodent
maintenance (RM) Atwater fuel energy (AFE) 45% fat, 20% crude protein (CP) and 35% carbohydrate
(CHO), obtained from Special Diets Services, Witham, UK), fenugreek seed flour (obtained from
Trigonella Med. Ltd., Mosonmagyarovar, Hungary), norepinephrine hydrochloride (NE; obtained
from the institutional drugstore as vial Arterenol®, Sanofi-Aventis, Franfurt, Germany), furthermore
diosgenin, acetylcholine chloride (Ach) and chemicals for Krebs solution (purchased from Sigma,
St. Louis, MO, USA).
Krebs solution contained (in mmol/L): NaCl: 118, KCl: 4.7, CaCl2: 2.5, NaH2PO4: 1, MgCl2: 1.2,
NaHCO3: 24.9, glucose: 11.5, and ascorbic acid: 0.1, dissolved in redistilled water. Krebs solution was
used to dissolve Ach, and to dilute the NE solution.
4.2. Animals and Protocols
The investigation was approved by the Committee of Animal Research, University of Debrecen,
Hungary (25/2013DEMÁB; date: 29 January 2014). Male Wistar rats weighting 300–500 g were
randomly divided in six groups: negative control group receiving conventional rat food and tap
water ad libitum (n = 6); positive control group receiving high-fat rat food and 5% m/v glucose
solution ad libitum as high-fat, high-sugar diet (HFHSD) (n = 6); fenugreek group treated with
2 g/kg bw/day fenugreek seed flour (containing 10 mg/kg bw/day diosgenin) in addition to HFHSD
(n = 9); diosgenin groups treated with 1, 10 and 50 mg/kg bw/day diosgenin in addition to HFHSD
(n = 8, 8 and 8, respectively). Fenugreek and diosgenin were added to the chow (at the beginning of
the HFHSD treatment). The daily dose was calculated on the basis of average daily food consumption
of the animals.
After 6 weeks, the animals were guillotined. Plasma glucose level was determined from the blood
using Accu-Chek Active meter (Roche Holding AG, Basel, Switzerland). Plasma insulin was measured
using ELISA kit (DA-INSULIN-2015; Cortez Diagnostics Inc., Woodland Hills, CA, USA). In addition,
blood was collected from each rat into EDTA-coated vacutainer tubes (BD, Franklin Lakes, NJ, USA)
to determine plasma concentrations of glutathione, glutathione-handling enzymes and antioxidant
capacity. The blood samples were centrifuged at 1000× g at 4 ◦C for 10 min. The plasma was divided
into aliquots and stored at −20 ◦C until analysis.
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4.3. Protocol of the Functional Assay
Immediately after guillotining (and collecting blood), the proximal part of the abdominal aorta
was isolated, and 2 mm wide rings were cut off (two rings from each animal). The rings were mounted
horizontally at 10 mN resting tension, using a wire instrument, in a 10-mL vertical organ chamber
(Experimetria TSZ-04, Experimetria Ltd, Budapest, Hungary) containing Krebs solution, oxygenated
with 95% O2 and 5% CO2 (36 ◦C; pH = 7.4). The isometric contractile force of the circulatory muscle
layer was measured by a transducer (Experimetria SD-01) and strain gauge (Experimetria SG-01D),
and recorded by a polygraph (Medicor R-61 6CH Recorder).
After a 60-min incubation period, a NE concentration-response (E/c) curve (from 0.1 nmol/L to
1 µmol/L) was generated on the aortic rings to determine their half maximal effective concentration
(EC50) value. After 60-min wash-out, EC50 for NE was administered to the rings, and, after the
stabilization of the contractile force at a higher value (pre-contraction), an Ach E/c curve was
constructed (from 0.1 nmol/L to 1 mmol/L).
4.4. Determination of Reduced (GSH) and Oxidized (GSSG) Glutathione
GSH and GSSG were determined using a commercially available assay kit (kit number: 703002;
Cayman Chemical, Ann Arbor, MI, USA). In the assay, 5,5′-dithio-bis (2-nitrobenzoic acid) (DTNB)
and GSH react and generate a yellow product (2-nitro-5-thiobenzoic acid). Under the assay
conditions, GSSG was reduced producing 2 molar equivalents of GSH. The absorbance was measured
colorimetrically at 405 nm for both GSH and GSSG, and sample concentrations were determined by
means of a standard GSH and GSSG curve expressing plasma concentrations in µmol/L (respectively).
4.5. Determination of Glutathione Peroxidase
Glutathione peroxidase activity was determined using a commercially available assay kit (kit
number: ab102530; Abcam Plc., Cambridge, UK). In this assay, glutathione peroxidase generates GSSG
from GSH during H2O2 reduction and the generated GSSG is reduced back to GSH by glutathione
reductase during consumption of NADPH. The reduction of NADPH is proportional to glutathione
peroxidase activity, thus, it can be measured colorimetrically at 340 nm. The kit reagents were dissolved
as described in the protocol book. The standard curve was prepared as described in the kit. 90 µL of
diluted standard solutions was added into the correct wells. 50 µL of samples, positive control and
reagent control was added to the plate into the correct well. The reaction mixture was as described
in the protocol book. The mix contained 33 µL of assay buffer, 3 µL of 40 mmol/L NADPH solution,
2 µL of glutathione reductase solution and 2 µL of GSH solution per well, except for standard wells.
40 µL of the reaction mix was added to the samples, positive control and reagent control. The plate
was incubated at room temperature for 15 min. After incubation, absorbance was measured. If the
absorbance value of the samples was lower than 1.0, then 1 µL of 40 mmol/L NADPH was added to
the sample. 1 µL of 40 mmol/L NADPH gave an ~0.5 increase in absorbance at 340 nm. After this step,
10 µL of cumene hydroperoxide was added to the samples, positive control and reagent control wells
to start the glutathione peroxidase reaction. The microplate reader was set to take 1 reading every
5 min for 30 min for glutathione reductase activity measurement. Measurements started immediately
after the addition of cumene hydroperoxide at 340 nm:
∆A340nm = (sample A1 − sample A2) − (reagent control A1 − reagent control A2)
where A1 is the absorbance value in the first reading, A2 is the absorbance data in the second reading.
An NADPH standard curve was plotted and ∆A340nm was applied to this curve to obtain ∆B for
NADPH. The obtained result was substituted into the equation:
glutathione peroxidase activity =
∆B
(T2 − T1) V D
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where ∆B is the amount of NADPH that decreased between T1 and T2 (in nmol), T1 is the time of the
first reading (A1) (min), T2 is the time of second reading (A2) (min), V is the pre-treated sample volume
added into the reaction well (mL), and D is the sample dilution factor. An NADPH standard curve
was plotted, and equations suggested by the kit were used. The activity of glutathione peroxidase was
expressed in nmol/min/mL = U/L.
4.6. Determination of Glutathione Reductase
Glutathione reductase activity was determined using a commercially available assay kit
(kit number: ab83461; Abcam Plc., Cambridge, UK). In this assay, glutathione reductase forms GSH
from GSSG, then, while GSH reacts with DTNB, a 2-nitro-5-thiobenzoate anion (TNB2−) is generated.
By measuring the change in absorbance at 405 nm, glutathione reductase activity can be determined
as follows:
glutathione reductase activity =
∆B
(T2 − T1) 0.9V D
where ∆B is the TNB amount from TNB standard curve (in nmol), T1 is the time of the first reading (A1)
(in min), T2 is the time of the second reading (A2) (in min), V is the pre-treated sample volume added
into the reaction well (in mL), 0.9 is the sample volume change factor during the sample pre-treatment
procedure, and D is the dilution factor, as suggested in the kit’s description. Glutathione reductase
activity was expressed in nmol/min/mL = U/L.
4.7. Determination of Antioxidant Capacity of Water-Soluble Compounds (ACW)
ACW was determined using a commercially available ACW kit (kit number: 846-60002-0;
Analytik Jena AG, Jena, Germany). Radicals were generated photochemically by UV irradiation
of a photosensitizer compound. PhotoChem measures the inhibition of radicals by the sample ACW
content. The ACW kit contains R1, R2, R3 and R4 reagents. R1 and R2 are ready for use and stored
at 2–8 ◦C. R3 is lyophilized and stored at −20 ◦C until use. 750 µL of R2 reagent was added into R3
and was ready to use. A stock solution was made from R4 reagent, 490 µL of R1 reagent and 10 µL
of H2SO4 were added into R4 reagent. 10-fold dilutions were made from the stock solution (10 µL of
R4 stock solution + 990 µL of R1 solution). First the blank was prepared: 1500 µL of R1, 1000 µL of
R2, and 25 µL of R3 were mixed. A calibration was made between 0.1 and 2 nmol (at least 5 points)
with L-ascorbic acid standard. The plasma sample was centrifuged at 10,000 rpm for 5 min and the
supernatant of samples was used for measurements. The working solution contained 1490 µL of R1,
1000 µL of R2, 25 µL of R3 and 10 µL of samples. The calculation for the lyophilized sample is:
concentration =
(results) (dilution) (176.13)
pipetted volume
The “result” is the result by the PhotoChem, 176.13 is the molecular weight of L-ascorbic acid,
pipetted volume is the sample volume (in µL). The final result was expressed as µg/mL L-ascorbic
acid equivalent.
4.8. Determination of Antioxidant Capacity of Lipid-Soluble Compounds (ACL)
ACL was determined using a commercially available ACL kit (kit number: 849-60004-0;
Analytikjena AG). The method is similar to that used for ACW test. The ACL kit contain R1, R2,
R3, and R4 reagents. R1 and R2 were ready for use but stored at 2–8 ◦C. R3 was lyophilized and stored
at −20 ◦C until use. 750 µL of R2 reagent was added into R3 and was ready to use. Stock solution
was made from R4 reagent: 500 µL of R1 reagent was added into R4 reagent, and 10-fold dilutions
were prepared from the stock solution (10 µL of R4 stock solution +990 µL of R1 solution. First the
blank was prepared: 2300 µL of R1, 200 µL of R2, and 25 µL of R3 were mixed. A calibration was made
between 0.2 nmol and 3 nmol (at least 5 points) with a trolox standard. The sample was centrifuged at
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10,000× g for 5 min. The supernatant of prepared samples was use for measurements. The working
solution contained 2290 µL of R1, 200 µL of R2, 25 µL of R3 and 10 µL of the samples. The calculation
for the lyophilized sample is:
concentration =
(results) (dilution) (250.3)
pipetted volume
The “result” means the result by the PhotoChem, 250.3 is the molecular weight of trolox, pipetted
volume is the sample volume (in µL). The final result was expressed as µg/mL trolox equivalent.
4.9. Data Processing and Analysis
Responses of aortic rings obtained from the same rat were averaged.
The effect of NE was defined as an (absolute) increase in addition to the resting tension (10 mN)
of aortic rings.
If relaxation occurred in the presence of a given Ach concentration, the maximal relaxation was
considered. If the ring produced a contraction, its maximum was taken into account. The effect of Ach
was defined as a percentage change in the initial tension of aortic rings (after the pre-contraction with
NE using their EC50 value).
Normality of data sets was verified with D’Agostino–Pearson omnibus test. Two data sets were
compared with unpaired, two-tailed Student’s t test or Welch’s t test (if variances were not equal).
More than two data sets were compared using one-way ANOVA (with Geisser–Greenhouse correction)
followed by Tukey post-testing. Difference of means was considered significant at p < 0.05. Statistical
analysis was carried out with GraphPad Prism 7.04 (GraphPad Software Inc., La Jolla, CA, USA).
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Abbreviations
4-OH-Ile 4-hydroxyisoleucine
ACC acetyl-CoA carboxylase
Ach acetylcholine
ACL lipid soluble antioxidant capacity
Act protein kinase B (PKB)
AMPK adenosine monophosphate-activated protein kinase
AWS water soluble antioxidant capacity
bw body weight
cGMP cyclic guanosine monophosphate
CHOP CCAAT-enhancer-binding homologous protein
CVD cardiovascular diseases
ED endothelial dysfunction
eNOS endothelial nitric oxide synthase
FFA free fatty acid
GLUT4 glucose transporter 4
GSH reduced glutathione (glutathione)
GSSG oxidized glutathione (glutathione disulfide)
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HDL high-density lipoprotein
HFHSD high-fat, high-sugar diet
ICAM intracellular adhesion molecule
IKK-β inhibitor of nuclear factor kappa-B kinase subunit beta
iNOS inducible nitric oxide synthase
IRS1 insulin receptor substrate 1
IκB inhibitor of kappa B
LDL low-density lipoprotein
LXRa liver X receptor-a
MAPK mitogen-activated protein kinase
MetS metabolic syndrome
mRNA messenger ribonucleic acid
NAFLD non-alcoholic fatty liver disease
NE norepinephrine
NF-κB nuclear factor kappa-light-chain-enhancer of activated B cells
nNOS neuronal nitric oxide synthase
NO nitric oxide
NOS nitric oxide synthase
PGI2 prostacyclin
PI3K phosphatidylinositol-4,5-bisphosphate 3-kinase
PPRγ peroxisome proliferator-activated receptor gamma
RAAS renin-angiotensin-aldosterone system
RNS reactive nitrogen species
ROS reactive oxygen species
SEM standard error of the mean
SREBPs sterol regulatory element-binding proteins
T2DM type 2 diabetes mellitus
TNF-α tumor necrosis factor alpha
VCAM vascular cell adhesion molecule
Appendix A
For the evaluation of an E/c curve, nonlinear regression (curve fitting) is a common method [74].
However, Ach E/c curves of the present investigation, in their original form, were not suitable for
curve fitting, because two opposite responses were evoked by Ach: a relaxation mediated by NO
(synthesized in the endothelial and perhaps arterial smooth muscle cells), and an NO-independent
contraction. Although, due to its greater EC50 value, this latter effect developed with a considerable
delay along the axis x, there was a significant overlap between the two opposite responses (as a
resultant, see Figure 3) that hindered the reliable fitting of the Hill equation, the most common choice
to assess an E/c relationship [75].
In order to quantify separately the NO-dependent relaxation and to make the regression more
reliable, Ach E/c data cleansing and manipulation were performed as follows. For each individual
Ach E/c curve (resulted from averaging of data of the two aortic rings obtained from the same animal),
the maximal effect value was chosen and arbitrarily assigned to all Ach concentrations that were
higher than the Ach concentration, to which the maximal effect belonged. Furthermore, zero effect was
assigned to three surely effectless Ach concentration values (1, 10, 100 fmol/L), and these E/c data
were arbitrarily added to each individual Ach E/c data set. These modified Ach E/c curves were fitted
to the Hill equation (in the GraphPad Prism software, the four-parameter log[agonist] vs. response
equation with a bottom constrained to zero).
The fenugreek- and diosgenin-treated aortic rings produced practically the same Ach-induced
arterial relaxation as the negative control aortic rings (representing the healthy state), and they all
showed more pronounced dilatory response to Ach than the positive control preparations (reflecting
the ED in an early-stage MetS) (Figure A1).
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Figure A1. The relationship between the concentration of acetylcholine (Ach) and the NO-mediated 
(so-called endothelium-dependent) arterial relaxation in experimental groups subjected to different 
diets, created from real Ach concentration-response (E/c) curves presented on Figure 3. The axis x 
shows the common logarithm of molar concentration of Ach, and the axis y indicates the effect as a 
percentage decrease of the initial contractile force. The symbols show the modified effect values 
averaged within the groups (±SEM), and the lines denote the Hill equation fitted to the averaged 
modified Ach E/c data. 
The Emax, logEC50 and n (Hill coefficient) parameters provided by the Hill equation (fitted to the 
individual modified Ach E/c data) were compared among the different experimental groups. Only 
differences of Emax values reached the level of statistical significance: Emax of the negative control 
group, 50 mg diosgenin group and fenugreek group significantly exceeded that of the positive control 
group (receiving HFHSD) (Table A1), in agreement with the results of analysis of real Ach E/c curves 
(Figure 3). Additionally, ED in the positive control group reflected in a moderately increased EC50, 
while beneficial effect of diosgenin and fenugreek prevented the deleterious action of HFHSD. 
Moreover, treatments with the highest diosgenin dose and fenugreek decreased EC50 even as 
compared to the negative control. The Hill coefficient values of the groups varied between 0.64 and 
0.73, excepting the fenugreek group, in which it increased to 0.85 (maybe as a results of the complex 
effect of different fenugreek components on the signaling pathways of Ach in the arterial wall) (Table 
A1). Our results yielded by curve fitting corroborate the findings obtained from the comparison of 
effect values of the intact Ach E/c curves (Figure 3). 
Table A1. Regression parameters (expressed in mean ± SEM) of the Hill equation fitted to the 
individual modified acetylcholine (Ach) concentration-response (E/c) curves. Level of statistical 
significance for differences between the positive vs. negative control groups (asterisk), and between 
the diosgenin and fenugreek treated groups vs. positive control group (hash mark) is indicated (*, #: 
p < 0.05). 
 Co− Co+ 1D 10D 50D FSF 
Emax 108.11 ± 6.05 79.66 ± 8.6 * 100.58 ± 11.31 111.12 ± 11.9 107.80 ± 5.56 # 101.84 ± 4.43 # 
logEC50 −7.94 ± 0.32 −7.65 ± 0.54 −7.95 ± 0.25 −7.95 ± 0.23 −8.3 ± 0.23 −8.45 ± 0.14 
n 0.67 ± 0.07 0.68 ± 0.07 0.73 ± 0.08 0.65 ± 0.07 0.64 ± 0.04 0.85 ± 0.1 
Co−: negative control group (receiving commercial rat diet); Co+: positive control group (receiving 
high-fat, high-sugar diet (HFHSD)); 1D, 10D and 50D: groups treated with 1, 10 and 50 mg/kg bw/day 
diosgenin in addition to HFHSD, respectively; FSF: group treated with 2 g/kg bw/day fenugreek seed 
flour (containing 10 mg/kg bw/day diosgenin); Emax: maximal effect; logEC50: common logarithm of 
EC50, the concentration producing half-maximal effect; n: Hill coefficient (slope factor). 
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The Emax, logEC50 and n (Hill coefficient) parameters provided by the Hill equation (fitted to
the individual modified Ach E/c data) were compared among the different experimental groups.
Only differences of Emax values reached the level of statistical significance: Emax of the negative
control group, 50 mg diosgenin group and fenugreek group significantly exceeded that of the positive
control group (receiving HFHSD) (Table A1), in agreement with the results of analysis of real Ach E/c
curves (Figure 3). Additionally, ED in the positive control group reflected in a moderately increased
EC50, while beneficial effect of diosgenin and fenugreek prevented the deleterious action of HFHSD.
Moreover, treatments with the highest diosgenin dose and fenugreek decreased EC50 even as compared
to the negative control. The Hill coefficient values of the groups varied between 0.64 and 0.73, excepting
the fenugreek group, in which it increased to 0.85 (maybe as a results of the complex effect of different
fenugreek components on the signaling pathways of Ach in the arterial wall) (Table A1). Our results
yielded by curve fitting corroborate the findings obtained from the comparison of effect values of the
intact Ach E/c curves (Figure 3).
Table A1. Regression parameters (expressed in mean ± SEM) of the Hill equation fitted to the
individual modified acetylcholine (Ach) concentration-response (E/c) curves. Level of statistical
significance for differences between the positive vs. negative control groups (asterisk), and between
the diosgenin and fenugreek treated groups vs. positive control group (hash mark) is indicated
(*, #: p < 0.05).
Co− Co+ 1D 10D 50D FSF
Emax 108.11 ± 6.05 79.66 ± 8.6 * 100.58 ± 11.31 111.12 ± 11.9 107.80 ± 5.56 # 101.84 ± 4.43 #
logEC50 −7.94 ± 0.32 −7.65 ± 0.54 −7.95 ± 0.25 −7.95 ± 0.23 −8.3 ± 0.23 −8.45 ± 0.14
n 0.67 ± 0.07 0.68 ± 0.07 0.73 ± 0.08 0.65 ± 0.07 0.64 ± 0.04 0.85 ± 0.1
Co−: negative control group (receiving commercial rat diet); Co+: positive control group (receiving high-fat,
hig -sugar diet (HFHSD)); 1D, 10D and 50 : groups treated with 1, 10 and 50 mg/kg bw/day diosgenin in addition
to HFHSD, respectively; FSF: group treated with 2 g/kg bw/day fenugreek seed flour (containing 10 mg/kg bw/day
diosgenin); Emax: maximal effect; logEC50: common logarithm of EC50, the concentration producing half-maximal
effect; n: Hill coefficient (slope factor).
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